论文部分内容阅读
目的检测分泌型卷曲相关蛋白1(SFRP1)基因在结直肠癌(CRC)患者血清中的甲基化状态,分析其临床意义。方法留取72例CRC患者术前血清标本及40例肠道良性病变血清标本,甲基化特异性聚合酶链反应(MS-PCR)检测SFRP1基因启动子区域甲基化状况。结果 72例CRC血清中,SFRP1基因甲基化比例为55.6%(40/72),而40例肠道良性病变患者中有4例发生甲基化(10.0%)(P<0.01)。SFRP1基因甲基化与患者临床病理特征及CEA、CA19-9水平无相关性。联合检测血清SFRP1甲基化及CEA、CA19-9水平可显著提高CRC检出率。结论血清SFRP1基因甲基化可望成为CRC诊断的新型分子标记,与传统肿瘤标记物的联合可进一步提高诊断率。
Objective To detect the methylation status of the secretory Frizzled Related Protein 1 (SFRP1) gene in the serum of patients with colorectal cancer (CRC) and analyze its clinical significance. Methods Seventy-two serum samples from patients with CRC and 40 patients with benign intestinal lesions were collected. Methylation-specific polymerase chain reaction (MS-PCR) was used to detect the methylation status of SFRP1 gene promoter region. Results The methylation of SFRP1 gene was found in 72 cases (55.6%, 40/72), while 4 of 40 cases (10.0%) had hypermethylation (P <0.01). There was no correlation between the methylation of SFRP1 gene and the clinicopathological features and CEA, CA19-9 levels. Combined detection of serum SFRP1 methylation and CEA, CA19-9 levels can significantly improve the detection rate of CRC. Conclusion Serum SFRP1 gene methylation is expected to become a new molecular marker for CRC diagnosis. Combined with traditional tumor markers, the diagnostic rate may be further increased.